ArticleFrontiers in medicine2026
Pulmonary cryptococcosis with or without immunocompromise: a retrospective comparative study of clinical and CT features and influential factors for lesion absorption.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary cryptococcosis (PC) is an invasive fungal infection with rising incidence in immunocompetent populations. The differential clinical and imaging characteristics between immunocompromised (ICP) and non-immunocompromised (NICP) patients remain incompletely characterized, limiting precision in diagnosis and management. Method: A retrospective study was conducted on 117 patients with confirmed PC from a single tertiary center. Patients were stratified into ICP and NICP groups based on refined criteria. Clinical symptoms, laboratory findings, and chest CT imaging features were systematically compared. Quantitative volumetric analysis was performed on follow-up CT scans ( Result: A high proportion of patients (59.0%) were asymptomatic at presentation. After False Discovery Rate (FDR) correction, no significant differences in clinical symptoms were found between ICP and NICP groups. Laboratory profiles, however, provided objective differentiation, with ICP patients showing significantly lower red blood cell counts and albumin levels (all Q < 0.05). CT imaging revealed that solitary nodules (Type I) were more common in NICP patients (Q = 0.030), while complex patterns like patchy consolidation (Type III) and numerous lesions (≥10) were significantly associated with ICP status (Q = 0.035). The halo sign was not a robust differentiator after FDR correction (Q = 0.105). Serum CrAg testing showed high diagnostic accuracy (83.9% positivity). In follow-up, a significantly lower DOA was observed in ICP patients (75.1% vs. 86.7%, Conclusions: The clinical presentation of PC is non-specific and cannot reliably differentiate immune status, underscoring the necessity of integrated laboratory and radiographic evaluation. ICP patients present with distinct laboratory abnormalities and more complex imaging patterns. Treatment response assessment should combine clinical, radiographic, and serological trends, as antigen persistence is common. From a clinical perspective, population-based screening is not recommended given the high proportion of incidentally discovered cases; instead, diagnostic vigilance during routine imaging should be emphasized. In immunocompetent patients with small solitary lesions, surgery alone represents an effective option that can reduce the need for prolonged antifungal therapy. Larger prospective studies are needed to validate the exploratory prognostic factors identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.